Urinary Cotinine as a Biomarker of Cigarette Smoke Exposure: A Method to Differentiate Among Active, Second-Hand, and Non-Smoker Circumstances



To review the literature on the use of urinary cotinine as a biological marker of cigarette smoke exposure.


Narrative review of original and review articles on the topic of interest, published in Portuguese or English by June 2018, and selected in the following online databases: PubMed and Virtual Health Library (VHL).


Urinary cotinine is usually the recommended biomarker to estimate exposure to cigarette smoke, and can be used alone or, preferably, in association with questionnaires. Different analytical techniques can be used to quantify urinary cotinine and are differently performed because of urine sample interfering factors.


The precise classification of smoking status is essential. It is advisable to use objective measurements regarding smoking habits since self-reported smoking may not always represent the true smoking status of the individual, particularly in groups that are more vulnerable to omitting the information of questionnaries, in addition, it has possible biases of memory. The accurate assessment of smoking is crucial to improve clinical management and counseling for different diseases as well as the establishment of preventive strategies. So, the use of urinary cotinine as a biomarker of cigarette smoke exposure seems to be a suitable assay to distinguish non-smokers from passive and active smokers.

Keywords: Biomarkers, Cotinine, Smoking, Exposure, Tobacco Smoke Pollution, Environmental Biomarkers.


Cigarette smoke exposure is one of the main risk factors associated with a marked increase in the risk of developing noncommunicable diseases, cardiovascular diseases, respiratory diseases and cancers [1]. It also translates into economic costs for patients, companies, and society as a whole. These may be direct, health care-related costs, or indirect, associated with a loss of productivity [2].The prevalence of smoking has reduced in Brazil, going from 15 to 13% between 2011 and 2013 [3, 4]. According to data from the Surveillance System for Risk and Protective Factors for Chronic Diseases by Telephone Survey (VIGITEL), in 27 Brazilian capitals, the percentage of adult smokers in the year 2017 ranged from 4.1 in Salvador to 15.6% in Curitiba [5].

Cigarette smoke is a heterogeneous mixture of gases and particulate matter composed of more than 7000 substances, although nicotine (i.e. a tertiary amine composed of a pyridine and a pyrrolidine) stands out as the main compound present in the tobacco leaf [6, 7], it has a relatively short half-life when compared the cotinine [8]. Cotinine is the main metabolite of nicotine biotransformation [9]. In brief, the CYP 2A6 transforms nicotine into a nicotine-delta-iminiun ion, followed by the enzyme aldehyde oxidase action to produce cotinine, and possibly four other cotinine metabolites, such as cotinine n´- oxide, trans-3´-hidroxy-cotinine, 5´-hidroxy-cotinine, and norcotinine [9]

Cotinine concentration is proportional to the degree of exposure to nicotine and can be measured in different body fluids, such as blood, urine, and saliva, as well as in nails and hair [10]. Among these, urine is the most suitable biological fluid to detect current and secondhand smoke exposure through the quantification of cotinine. Even in situations of low exposure, the use of urine proves appropriate due to the possibility of estimating recent exposure and of showing higher concentrations, thus facilitating the use of different analytical techniques [10, 11]. The ideal time for measurement is 4 to 8 hours after exposure, at which point the maximum levels of this biomarker can be observed [12].

In addition, cotinine concentration can be calculated directly or corrected by urinary creatinine concentration to make this biomarker method even more accurate by normalizing the results through urine dilution [11]. Although multiple measurements reduce the incidence of classification errors, a single measurement of this biomarker can accurately determine the level of exposure to tobacco smoke [13].

Determining urinary cotinine concentration has been recommended in several situations, such as monitoring of cigarette smoke exposure, even during pregnancy and in some risk groups [7, 14]; impact assessment of smoking cessation programs [15]; occupational exposure assessment [16] and; exposure to environmental pollutants [17]. Therefore, this study aimed to review the literature on the use of urinary cotinine as a biomarker of cigarette smoke exposure and the methods used for its quantification.


A narrative review of the literature was carried out by using the following online databases: PUBMED and Virtual Health Library (VHL), which includes LILACS, IBECS, MEDLINE, Cochrane Library and SciELO. The search was conducted between April and June 2018, based on the combination of selected keywords and the Boolean Operators “AND” and “OR”.

Original and review articles on the subject, in Portuguese and in English, available in full version and published by June 2018, were selected by using the following keywords: biomarkers, cotinine, smoking, and exposure. The references of the articles were also checked in order to locate those that could not be found in the databases.


3.1. Assessment of Tobacco Exposure: Urinary Cotinine Versus Self-Report

Self-reported smoking using questionnaires has been the most widely used tool to assess exposure to cigarette smoke, however, this strategy may underestimate smoking habits. Some authors suggest that self-reporting should be associated with the analysis of specific biomarkers, especially in groups which are more likely to omit information [18, 19].

Markers of tobacco smoke exposure allow an estimation of the degree of exposure to cigarette smoke. In this scenario, cotinine is the main metabolite of nicotine and, therefore, largely used as a biological marker of exposure. However, the analysis of biomarkers, including urinary cotinine, depends on information obtained through self-report, which is used as a reference for the estimation of cutoff values that help define smoking status [20]. Although some cutoff values for urinary cotinine are more commonly adopted in the literature (Table 1), there is no consensus and some authors suggest that these values should be specific for each population [21].

In fact, active smokers show high levels of urinary cotinine, and the cutoff points described in the literature would be adequate for their identification. On the other hand, the differences between the other groups (i.e. exposure to secondhand smoke and non-smokers) are less clear and require different strategies to estimate cutoff points based on the data obtained by self-report and, therefore, to define ​​more appropriate values to such populations [22, 23].

Self-report questionnaires are the main form of smoking assessment among pregnant women, however, confirmation by laboratory analysis allows correct and reliable classification [24]. In addition, double-monitoring strategies using questionnaires and urinary cotinine quantification have been used to obtain information on the smoking status and the exposure to cigarette smoke from different sources among various population groups, such as pregnant women, university students and renal transplant recipients [21, 25, 26]

In pregnant women, smoking concealment is frequent due to the influence of social factors. The same is true for patients suffering from diseases with a strong correlation with smoking, such as chronic obstructive pulmonary disease, and head and neck cancer. In these cases, self-reported smoking had no correlation with the concentration of carcinogenic metabolites, unlike urinary cotinine [18, 27, 28]. In children, secondhand smoke exposure estimates are usually obtained through the self-report of their parents or caregivers, who are likely to be the source of exposure. Therefore, accurate and objective measurements are crucial, with the use of urinary cotinine concentration being a noninvasive option widely described in the literature for this age group [29].

Also, assessing cigarette smoke exposure using both urinary cotinine quantification and questionnaires in early life allows us to estimate the risk of recurrent wheezing and asthma in childhood. In addition, smoke exposure is closely related to the greater presence of daily symptoms of asthma and its assessment helps in the identification of children at higher risk of experiencing an asthma crisis aggravation [29-31].

It is recognized that cotinine is the better predictor of birth weight than self-reported per-day tobacco use [32]. Most studies of reproductive consequences that were based on cotinine body fluid levels such as urine of mother or neonate demonstrate a better correlation between higher cotinine level and poor neonatal outcome [33, 34].

In all of these cases, the analysis of tobacco biomarkers is an indispensable tool that can be used independently to measure the exposure to cigarette smoke or, preferably, together with questionnaires.

3.2. Urinary Cotinine for Measuring Exposure to Secondhand Smoke

Exposure to secondhand smoke is defined as the exposure to the smoke that comes from the direct burning of cigarettes or other tobacco products, usually in combination with the smoke exhaled by the smoker, with harmful effects on the health of the exposed individual. The exposure of non-smokers to cigarette smoke depends on some factors, such as the room ventilation rate, the proximity of smokers to non-smokers, number of cigarettes smoked, among others [2]. For example, in seamen volunteers recruited from submarines, it was observed that the urinary cotinine levels of non-smoker on board were 2.1 times higher than at the seaport [35].

Cotinine is also the biomarker of choice for the quantification of exposure to secondhand smoke. It is possible to establish a dose-response relationship between the intensity and duration of exposure and the amount of cotinine excreted in the urine [36] since urinary cotinine is highly correlated with active and passive smoking [37]. Some authors believe that urinary cotinine concentration is a useful biomarker to distinguish non-smokers from current smokers. However, a careful interpretation of the cotinine concentration is necessary to estimate passive exposure to cigarette smoke [14].

The effects of secondhand smoke on children can be seen through respiratory diseases, infections, reduced school performance, and neurobehavioral problems [38]. Therefore, more effective strategies should be implemented towards protecting this population, which represents the most susceptible group to the harmful effects of environmental tobacco smoke exposure [38]. Urinary cotinine levels in children tend to vary depending on the number of household smokers or involved in their daily activities, the parents' perception of the tobacco exposure effects on children, the family members number of cigarettes smoked per day, and the exposure duration at home [39-41].

Just as it is the case for children, bar and restaurant staff are also a vulnerable population when it comes to secondhand smoke exposure. Promoting smoking cessation programs and occupational rules regarding smoking prohibition can have a significant impact on public health, and the measurement of urinary cotinine can be a valuable form of biological monitoring. In an experimental study with bar staff after the implementation of anti-smoking laws, there was a significant reduction in mean urinary cotinine concentration, from 35.9 ng / mL to below the limit of quantification (5 ng / mL), as well as in self-reported respiratory symptoms [42]. Therefore, it is clear that measures focused on occupational health such as the implementation of policies for smoke-free places are extremely relevant.

3.3. Analytical Methodologies for Determination of Urinary Cotinine

Urinary cotinine can be quantified by several analytical techniques, such as High- Performance Liquid Chromatography (HPLC); Gas Chromatography (GC); thin-layer chromatography; Enzyme-Linked Immunosorbent Assay (ELISA); chemiluminescent immunoassay; radioimmunoassay. Mass spectrometry or ultraviolet absorption detectors have been widely applied for the detection of cotinine in chromatographic techniques (Table 1).

Despite their high sensitivity, the immunoassays specificity is low for cotinine quantification due to cross-reactions with other nicotine metabolites, such as 3-hydroxycotinine and 3-hydroxycotinine glucuronide; on the other hand, their acquisition and operating costs are lower and they can be very useful as a screening assay, especially when used in new high throughput systems, which can be highly efficient [25, 43]. In addition, immunoassays can also be complementary to the analyses conducted with chromatographic techniques, helping achieve greater selectivity when required [26].

Chromatographic techniques are primarily separation methods with high analytical specificity as they are able to separate structurally related metabolites from nicotine. In addition, their high sensitivity allows the limit of quantification for cotinine to be as low as 0.05 ng / mL when using liquid chromatography-mass spectrometry [12]. Chromatography-based methods can selectively quantitate free cotinine in urine. Some authors have also been performing cotinine-N-glucuronide hydrolysis using alkaline or enzymatic hydrolysis in order to determine total cotinine (i.e. free and conjugated) [29, 37].

However, different chromatographic techniques such as thin-layer chromatography, liquid chromatography, and gas chromatography can be used to detect cotinine; as a limitation, to detect cotinine these methods are more expensive and time-consuming. Usually, such techniques require urine samples prior to treatment to cotinine quantification, which may be done by purification through previous chromatography, solid-phase extraction or liquid-liquid extraction [21, 23, 44].

3.4. Variability in Urinary Cotinine Concentration

Urine cotinine levels tend to be influenced by environmental factors related to the intensity and duration of exposure to tobacco smoke, the amount of nicotine in the cigarette, the size and ventilation of the place of exposure.

Several factors influence the metabolism of nicotine, such as ethnic differences, Black and Asian individuals have a lower nicotine metabolism rate when compared to White people [45]; dietary habits, because some types of food have nicotine in their composition, which may increase the cotinine metabolite levels [46]; age, newborns have prolonged elimination of nicotine, but similar elimination of cotinine and other conjugated metabolites. This may be caused by the difference in the action of the CYP2A6 enzyme, which is responsible for the metabolism of these substances [47]. Moreover, the elderly tend to have reduced renal clearance of cotinine compared to adults [48], and during pregnancy, metabolic clearance of cotinine is markedly accelerated, resulting in a shorter half-life when compared to non-pregnant women [49]. On the other hand, individuals with severe renal impairment have reduced metabolic clearance of nicotine by about 50% when compared to healthy subjects [50].

Table 1.
Studies using urinary cotinine as a biomarker of tobacco smoke exposure, published in the last five years.
Author, (year) Study Design Study Population Level of Exposure Analytical Method Urinary Cotinine Concentration
Paci, et al., 2018 Cross-sectional study 1,075 individuals Smokers: 27.5% HPLC-MS Cutoff point: 100 µg/g creat.
Median - smokers: 1,504.7 ug/g creat.
Median - non-smokers: 5.6 ug/g creat.
Perry et al., 2018 Case-control study 295 individuals Urinary cotinine was detected in 60 children subject to exposure at home (parents' self-report) and 14 children whose parents denied exposure. MS Cutoff point: > 5 μg/L.
Moon et al., 2017 Cross-sectional study 276 employees at tobacco and hookah smoking places Median creatinine concentration (interquartile): 1.1 (0.2 - 40.9) μg / g. Enzyme-linked immunosorbent assay kit. Limit of detection: 2 mg/dL.
Kim et al., 2018. Cross-sectional study 96,806 medical records of asymptomatic individuals subjected to colonoscopy Active smokers: 23%
Non-smokers: 77%
DRI cotinine assay using a
modular P800 chemistry analyzer.
Cutoff point: ≥50 ng/mL
Benowitz et al., 2018 Cross-sectional study 469 adolescents Adolescents with cotinine levels above the limit of quantification: 407 (87%). LC-MS Limit of quantification: 0.05 ng /mL.
Nam et al., 2017 Cross-sectional study 1,139
N.I. GC-MS Limit of detection: 0.26 ng/mL.
Wang, et al.,
Cross-sectional study 368 children and their parents Children living with 2 or more smokers: 30.7%;
Children living with 1 smoker: 69.3%.
GC-MS Geometric mean for children: 3.94 ng / mL.
Martinez-Sanchez, et al., 2017 Cross-sectional study 49 non-smokers Individuals living with smoker(s): 25 LC-MS Perception of intensity of exposure (Median)
   High: 7.59 ng/mL;
   Medium: 3.57 ng/mL;
   Low: 1.25 ng/mL;
   Very low: 0.44 ng/mL.
Rifai, et al., 2017 Cross-sectional study 843 active smokers 1 to 10 cigarettes/day: 299
10 to 20 cigarettes/day: 443
>20 cigarettes/day: 101
Immulite 2000 Assay Tercile 1: 7 - 2421 ng/mL;
Tercile 2: 2422- 6436 ng/mL;
Tercile 3: > 6437 ng/mL.
Hoseini, et al.,
Cross-sectional study 222 urban residents Active smokers: 76
Passive smokers: 57
Non-smokers: 89
ELISA Cutoff point(active): 100 ng/mL
Active smoker: 795.6 ± 396.7 ng/mL;
Passive smoker: 7.6 ± 2.8 ng/mL;
Non-smoker: 3.56 ± 1.9 ng/mL.
Tranfo et al., (2016) Descriptive study 446 healthy volunteer residents Smokers: 93
Former smokers: 156
Non-smokers: 197
HPLC-MS Limit of detection: 12.41 μg/L.
Cutoff point (smokers): 100 μg/g creatinine.
> 100 ug/g creatinine: 110
Hellemons, et al. (2015) Prospective cohort 603 renal transplant recipients Never smoked: 217
Former smokers: 255
Light smokers: 64
Heavy smokers: 67
Immulite 2500 Assay Limit of detection: 10 ng/mL.
Cutoff point
    Non-smokers: < 100 ng/mL;
    Passive smokers: 100-500 ng/mL;
    Active smokers: >500 ng/mL;
Lupsa, et al.
Cross-sectional study 360 children and their mothers Mothers
  Daily smokers: 89
  Occasional smokers: 30
  Former smokers: 62
  Non-smokers: 179
HPLC-MS Limit of quantification: 0.7 ug/L.
Different cutoff points for each subpopulation.
Evlampidou, et al., (2015) Cohort 175 pairs of non-smoking mothers-children Children with no exposure to secondhand smoke at 8 months (mothers' self-report): 56% GC-MS Total Cotinine (free + glucuronide)
   Limit of detection: 1.0 ng/mL.
   Cutoff point: 100 ng/mL
Mørck, et al., (2015) Cross-sectional study 75 pairs of mothers/children from urban areas;
70 pairs of mothers/children from rural areas
Smoking mothers from urban areas: 6
Smoking mothers from rural areas: 12
LC-MS Limit of detection: 0.3 ug/L.
Children's maximum value: 16.3 ug/L;
Mothers' maximum value: 3.403 ug/L;
All smoking mothers: > 200 ug/L
Wang, et al., (2015) Randomized controlled trial 65 children aged 5 to 6 years and caregivers.
  33 pairs received intervention (smoking cessation education);
  32 control pairs.
Cessation after 6 months
   Intervention group: 34.4%;
   Control group: 0%
GC-MS Limit of quantification: 0.1 ng /mL.
Khariwala, et al.
Cross-sectional study 84 smokers with head and neck cancer N.I. GC-MS Urinary cotinine levels correlated with carcinogen levels.
Stelmach, et al. (2015) Cross-sectional study 144 individuals with Asthma (51) or Chronic Obstructive Pulmonary Disease (53) Smokers: 20
Never smoked: 20
HPLC-UV Median concentration
   Smokers: 2036 ng/mL;
   Never smoked: 70 ng/mL;
   COPD: 167 ng/mL;
   Asthma: 47 ng/mL.
Jones, et al.
Experimental exposure 10 participants Non-smokers: 08
Active smokers: 02
LC-MS Total Cotinine.
Limit of quantification: 0.05 ng /mL.
Khariwala, et al.
Cross section 28 black individuals, 04 Latinos and 25 whites from one community Smoked at least 1 cigarette in 4-24 days in the last 30 days. LC-MS Limit of quantification: 0.05 ng /mL.
Mean (standard deviation): 804.40 (917.76) ng / mg creatinine; Median: 409.9 ng / mg creatinine.
Martinez-Sanchez, et al., 2017
Observational study 49 non-smoking volunteers from different households People living with smoker(s): 25;
People living in non-smoking households: 24.
LC-MS Limit of quantification: 0.10 ng /mL.
Median: 0.92 ng/mL.
Gill; Krishnan; Dozor, 2014 Cross-sectional study 40 individuals aged 8-18 years, with mild to moderate persistent asthma. Individuals affected by secondhand smoke exposure: 28 (70%). ELISA Indication of exposure to secondhand smoke: ≥ 1 ng / mL.
Mateos-Vílchez, et al. (2014) Cross-sectional study 1,813 women from 03 independent samples: beginning, end of pregnancy and immediate postpartum period. Tobacco exposure (active and passive smoking)
     End of gestation: 25.0%;
     Beginning of gestation: 41.8%;
Competitive chemiluminescent immunoassay Non-smokers: < 20 ng/mL;
Passive or occasional smokers: 20-125 ng / mL; Moderate smokers: 125-500 ng / mL;
Heavy smokers: > 500 ng / mL.
Machado, et al. (2014) Cross-sectional study 125 pregnant women Current smokers: 37;
Individuals subject to secondhand smoke exposure: 25
Non-smokers: 63
HPLC-UV Urinary cotinine limit of quantification: 10 ug / L.
Matsumoto, et al. (2013) Cross-sectional study 219 people from a manufacturing company. Smokers: 102;
Non-smokers: 117
GC-MS Limit of quantification: 0.7 ng /mL.
Smokers: 3.948 ng/mL;
Non-smokers: < 2.8 ng/mL;
Szumska, et al. (2013)
Tyrpién, et al. (2000)
Cross-sectional study 85 medical students Active smokers: 40
Non-smokers: 45
    Exposed: 25
    Not exposed: 20
ELISA for nicotine metabolites, followed by C18 TLC with densitometry ELISA (nicotine metabolites)
Smokers: > 200 μg/g creatinine;
Non-smokers: <200 μg / g creatinine;
    Passive smoker: 20-200 μg / g creatinine;
    Not exposed: <20 μg / g creatinine.
Limit of detection: 13.5 ng/spot.
Smokers: 523.1 ± 68.1 ug/g creatinine;
    Exposed: 40.89 ± 24.8 μg cotinine /g creatinine.
    Not exposed: not detected.
Vardavas, et al. (2013) Cohort 367 non-smoking pregnant women Exposure to secondhand cigarette smoke
   > 2 sources of exposure: 158;
   ≤ 2 sources of exposure: 209
LC-MS Total Cotinine.
Limit of quantification: 0.5 ng /mL.
Household exposure: 4.40 ng / mL increase;
Secondhand smoke exposure in cars: 8.73 ng / mL increase.
Yarnall, et al.
Longitudinal study 239 volunteers recruited from US Navy submarines. Pairs of non-smoker samples at seaport (before embarking) and after disembarking: 206 LC-MS Limit of detection: 0.05 ng/mL.
Cutoff point(smoker): 15 ng/mL
Kim, et al.
Cross-sectional study 925 post-menopause women Never smoked GC-MS Limit of detection: 0.28 ng/mL.
Pacheco, et al., (2013) Cross-sectional study 96 workers Smokers: 26;
Non-smokers: 70.
GC-MS Limit of quantification: 5 ng /mL.
*Abbreviations: LC: Liquid chromatography; MS: Mass Spectrometry; GC: Gas Chromatography; ELISA: Enzyme-linked immunosorbent assay; HPLC: High-performance liquid chromatography; UV: Ultraviolet; N.I.: No Information; ln: natural logarithm.

There is evidence that genetic polymorphisms related to nicotine metabolism constitute an important factor in the susceptibility to nicotine dependence; genetic discoveries may allow the identification of individuals at greater risk of tobacco dependence and be used as a more effective strategy in the treatment and prevention of smoking [9, 51]. Understanding interindividual variability in nicotine metabolism is crucial, as there is substantial evidence to suggest that interindividual differences in cotinine production can be associated with CYP2A6 gene polymorphisms [52]. Japanese individuals, for example, have low CYP2A6 activity, an enzyme necessary for nicotine to be metabolized into cotinine [53].

Another important factor to estimate exposure to cigarette smoke is the establishment of cutoff points for more objective differentiation levels of exposure based on urinary cotinine concentration [54]; thus, factors influencing cotinine levels in urine should be considered in order to ensure better differentiation in the studied population.


Urinary cotinine is a reliable biomarker, widely used for distinguishing between active and secondhand smoke exposure. Although several highly sensitive analytical methodologies such as chromatography or immunoassay can be used for the urinary cotinine quantification, it should be preferably used in association with self-reports interviews or questionnaires, to correctly estimate the most appropriate cutoff points for smoking status classification.


Not Applicable.


We thank CNPq, FAPESB, and CAPES – finance Code 001, for the scholarships, financial grants, and infrastructural support.


The manuscript authors declare no conflict of interest. This paper was written by using secondary data information, and none of this content has been previously published.


We thank Dr. Álvaro Augusto Souza da Cruz Filho for the everlasting mentoring and friendlily teaching.


Ghasemian A, Rezaei N, Saeedi Moghaddam S, et al. Tobacco Smoking Status and the Contribution to Burden of Diseases in Iran, 1990-2010: findings from the Global Burden of Disease Study 2010. Arch Iran Med 2015; 18(8): 493-501.
WHO. Protection from exposure to second-hand tobacco smoke. Policy recommendations. 2007. Available from: https://apps.who. int/iris/bitstream/handle/10665/43677/ 9789241563413_eng.pdf;jsess ionid=F2A13DFF6729CB01ADCC138BFC1927DC?sequence=1
Organization WH. WHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship 2013.
WHO. WHO report on the global tobacco epidemic, 2015: raising taxes on tobacco 2015.
Brasil Vigitel Brasil 2016: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico : estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados b 2017.
Eriksen J, Schluger N, Islami F, Drope JMM. https://tobaccoatlas.org/
Haufroid V, Lison D. Urinary cotinine as a tobacco-smoke exposure index: a minireview. Int Arch Occup Env Heal [Internet]. 1998;71(3):162–8. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/9591157
Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit 2009; 31(1): 14-30.http://www.ncbi.nlm.nih.gov/ pubmed/19125149
Tutka P, Mosiewicz J, Wielosz M. Pharmacokinetics and metabolism of nicotine. Pharmacol Rep 2005; 57(2): 143-53.http://www.ncbi.nlm. nih.gov/pubmed/15886412
Avila-Tang E, Al-Delaimy WK, Ashley DL, et al. Assessing secondhand smoke using biological markers. Tob Control 2013; 22(3): 164-71.http://www.ncbi.nlm.nih.gov/pubmed/22940677
Benowitz NL, Dains KM, Dempsey D, Herrera B, Yu L, Jacob P III. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res 2009; 11(8): 954-60.http://www.ncbi.nlm.nih.gov/pubmed/19525206
Jones IA, St Helen G, Meyers MJ, et al. Biomarkers of secondhand smoke exposure in automobiles. Tob Control 2014; 23(1): 51-7.https://www.ncbi.nlm.nih.gov/pubmed/23349229
Lee K, Lim S, Bartell S, Hong YC. Interpersonal and temporal variability of urinary cotinine in elderly subjects. Int J Hyg Env Heal [Internet]. 2011;215(1):46–50. Available from: http://www.ncbi.nlm.nih. gov/pubmed/21900044
Jung S, Lee IS, Kim SB, et al. Urine Cotinine for Assessing Tobacco Smoke Exposure in Korean: Analysis of the Korea National Health and Nutrition Examination Survey (KNHANES). Tuberc Respir Dis [Internet]. 2012/10/31. 2012;73(4):210–8. Available from: https://www.ncbi.nlm.nih.gov/ pubmed/23166556
Wang Y, Huang Z, Yang M, Wang F, Xiao S. Reducing environmental tobacco smoke exposure of preschool children: a randomized controlled trial of class-based health education and smoking cessation counseling for caregivers. Int J Env Res Public Heal [Internet]. 2015;12(1):692–709. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/25590146
Pacheco SA, Torres VM, Louro H, et al. Effects of occupational exposure to tobacco smoke: is there a link between environmental exposure and disease? J Toxicol Environ Health A 2013; 76(4-5): 311-27.https://www.ncbi.nlm.nih.gov/pubmed/23514073
Sul D, Ahn R, Im H, et al. Korea National Survey for Environmental Pollutants in the human body 2008: 1-hydroxypyrene, 2-naphthol, and cotinine in urine of the Korean population. Environ Res 2012; 118: 25-30.http://www.ncbi.nlm.nih.gov/pubmed/22939007
Stelmach R, Fernandes FL, Carvalho-Pinto RM, et al. Comparison between objective measures of smoking and self-reported smoking status in patients with asthma or COPD: are our patients telling us the truth? J Bras Pneumol 2015; 41(2): 124-32.http://www.ncbi.nlm.nih. gov/pubmed/25972966
Connor Gorber S, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res 2009; 11(1): 12-24.http://www.ncbi. nlm.nih.gov/pubmed/19246437
Zielińska-Danch W, Wardas W, Sobczak A, Szołtysek-Bołdys I. Estimation of urinary cotinine cut-off points distinguishing non-smokers, passive and active smokers. Biomarkers 2007; 12(5): 484-96.https://www.ncbi.nlm.nih.gov/pubmed/17701747
Lupsa IR, Nunes B, Ligocka D, et al. Urinary cotinine levels and environmental tobacco smoke in mothers and children of Romania, Portugal and Poland within the European human biomonitoring pilot study. Environ Res 2015; 141: 106-17.http://www.ncbi.nlm.nih. gov/pubmed/25841796
Hoseini M, Yunesian M, Nabizadeh R, Yaghmaeian K, Parmy S, Gharibi H, et al. Biomonitoring of tobacco smoke exposure and self-reported smoking status among general population of Tehran, Iran. Env Sci Pollut Res Int [Internet]. 2016/09/27. 2016;23(24):25065–73. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27677995
Mørck TA, Nielsen F, Nielsen JK, et al. The Danish contribution to the European DEMOCOPHES project: A description of cadmium, cotinine and mercury levels in Danish mother-child pairs and the perspectives of supplementary sampling and measurements. Environ Res 2015; 141: 96-105.https://www.ncbi.nlm.nih.gov/pubmed/ 25440293
Stragierowicz J, Mikołajewska K, Zawadzka-Stolarz M, Polańska K, Ligocka D. Estimation of cutoff values of cotinine in urine and saliva for pregnant women in Poland. BioMed Res Int 2013; 2013386784http://www.ncbi.nlm. nih.gov/pubmed/24228246
Hellemons ME, Sanders JS, Seelen MA, et al. Assessment of Cotinine Reveals a Dose-Dependent Effect of Smoking Exposure on Long-term Outcomes After Renal Transplantation. Transplantation 2015; 99(9): 1926-32.http://www.ncbi.nlm.nih.gov/pubmed/25710609
Szumska M, Tyrpień K, Kowalska M, Wielkoszyński T, Dobosz C. Medicine students and exposure to environmental tobacco smoke. Int J Occup Med Env Heal [Internet]. 2013;26(2):313–20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23771859
Khariwala SS, Carmella SG, Stepanov I, et al. Self-reported Tobacco use does not correlate with carcinogen exposure in smokers with head and neck cancer. Laryngoscope 2015; 125(8): 1844-8.http://www.ncbi. nlm.nih.gov/pubmed/25877866
Mateos-Vílchez PM, Aranda-Regules JM, Díaz-Alonso G, et al. [Smoking prevalence and associated factors during pregnancy in Andalucía 2007-2012]. Rev Esp Salud Publica 2014; 88(3): 369-81.http://www.ncbi.nlm.nih.gov/pubmed/25028305
Butz AM, Breysse P, Rand C, Curtin-Brosnan J, Eggleston P, Diette GB, et al. Household smoking behavior: effects on indoor air quality and health of urban children with asthma. Matern Child Heal J [Internet]. 2011;15(4):460–8. Available from https://www.ncbi.nlm. nih.gov/pubmed/ 20401688
Carlsten C, Dimich-Ward H, DyBuncio A, Becker AB, Chan-Yeung M. Cotinine versus questionnaire: early-life environmental tobacco smoke exposure and incident asthma. BMC Pediatr 2012; 12: 187.https://www.ncbi.nlm.nih.gov/pubmed/23216797
Rabinovitch N, Reisdorph N, Silveira L, Gelfand EW. Urinary leukotriene E4 levels identify children with tobacco smoke exposure at risk for asthma exacerbation. J Allergy Clin Immunol 2011; 128(2): 323-7.https://www.ncbi.nlm.nih.gov/pubmed/21807251
Spector LG, Murphy SE, Wickham KM, Lindgren B, Joseph AM. Prenatal Tobacco Exposure and Cotinine in Newborn Dried Blood Spots. Pediatrics [Internet]. 2014 Jun 1 [cited 2019 Mar 31];133(6):e1632–8. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/24819573
England LJ, Kendrick JS, Gargiullo PM, Zahniser SC, Hannon WH. Measures of maternal tobacco exposure and infant birth weight at term. Am J Epidemiol [Internet]. 2001 May 15 [cited 2019 Mar 31];153(10):954–60. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/11384951
Braun JM, Daniels JL, Poole C, Olshan AF, Hornung R, Bernert JT, et al. A prospective cohort study of biomarkers of prenatal tobacco smoke exposure: the correlation between serum and meconium and their association with infant birth weight. Environ Health [Internet]. 2010 Aug 27 [cited 2019 Mar 31];9(1):53. Available from: http://ehjournal.biomedcentral.com/articles/10.1186/1476-069X-9-53
Yarnall NJ, Hughes LM, Turnbull PS, Michaud M. Evaluating the effectiveness of the US Navy and Marine Corps Tobacco Policy: an assessment of secondhand smoke exposure in US Navy submariners. Tob Control 2013; 22(e1): e66-72.http://www.ncbi.nlm.nih.gov/ pubmed/22871902
Martínez-Sánchez JM, Sureda X, Fu M, et al. Secondhand smoke exposure at home: assessment by biomarkers and airborne markers. Environ Res 2014; 133: 111-6.http://www.ncbi.nlm.nih.gov/ pubmed/24912142
Matsumoto A, Ichiba M, Payton NM, Oishi H, Hara M. Simultaneous measurement of urinary total nicotine and cotinine as biomarkers of active and passive smoking among Japanese individuals. Env Heal Prev Med [Internet]. 2013;18(3):244–50. Available from: http://www.ncbi.nlm. nih.gov/pubmed/23011941
Hwang SH, Hwang JH, Moon JS, Lee DH. Environmental tobacco smoke and children’s health. Korean J Pediatr 2012; 55(2): 35-41.https://www.ncbi.nlm.nih.gov/pubmed/22375147
Wang Y, Yang M, Huang Z, Tian L, Niu L, Xiao S. Urinary cotinine concentrations in preschool children showed positive associations with smoking fathers. Acta Paediatr 2017; 106(1): 67-73.https://www.ncbi. nlm.nih.gov/pubmed/27748973
Martínez-Sánchez JM, González-Marrón A, Martín-Sánchez JC, Sureda X, Fu M, Pérez-Ortuño R, et al. Validity of self-reported intensity of exposure to second-hand smoke at home against environmental and personal markers. Gac Sanit 2017; 2017https://www.ncbi.nlm.nih.gov/pubmed/29102505
Jurado D, Muñoz C, Luna JdeD, Fernández-Crehuet M. Environmental tobacco smoke exposure in children: parental perception of smokiness at home and other factors associated with urinary cotinine in preschool children. J Expo Anal Environ Epidemiol 2004; 14(4): 330-6.https://www.ncbi.nlm.nih.gov/pubmed/15254480
Wilson T, Shamo F, Boynton K, Kiley J. The impact of Michigan’s Dr Ron Davis smoke-free air law on levels of cotinine, tobacco-specific lung carcinogen and severity of self-reported respiratory symptoms among non-smoking bar employees. Tob Control 2012; 21(6): 593-5.https://www.ncbi.nlm.nih.gov/pubmed/22705599
Matsumoto A, Ino T, Ohta M, Otani T, Hanada S, Sakuraoka A, et al. Enzyme-linked immunosorbent assay of nicotine metabolites. Env Heal Prev Med [Internet]. 2010/01/08. 2010;15(4):211–6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21432547
Machado JdeB, Chatkin JM, Zimmer AR, Goulart AP, Thiesen FV. Cotinine and polycyclic aromatic hydrocarbons levels in the amniotic fluid and fetal cord at birth and in the urine from pregnant smokers. PLoS One 2014; 9(12)e116293http://www.ncbi.nlm.nih.gov /pubmed/25549364
Rubinstein ML, Shiffman S, Rait MA, Benowitz NL. Race, gender, and nicotine metabolism in adolescent smokers. Nicotine Tob Res [Internet]. 2012/12/13. 2013;15(7):1311–5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23239845
Davis RA, Stiles MF, deBethizy JD, Reynolds JH. Dietary nicotine: a source of urinary cotinine. Food Chem Toxicol 1991; 29(12): 821-7.http://www.ncbi.nlm.nih.gov/pubmed/1765327
Dempsey D, Jacob P III, Benowitz NL. Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther 2000; 67(5): 458-65.http://www.ncbi.nlm.nih.gov/pubmed/10824624
Molander L, Hansson A, Lunell E. Pharmacokinetics of nicotine in healthy elderly people. Clin Pharmacol Ther 2001; 69(1): 57-65.https://www.ncbi.nlm.nih.gov/pubmed/11180039
Dempsey D, Jacob P III, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 2002; 301(2): 594-8.http://www.ncbi.nlm.nih.gov/pubmed/11961061
Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R. Pharmacokinetics of nicotine in kidney failure. Clin Pharmacol Ther 2000; 68(3): 250-60.https://www.ncbi.nlm.nih.gov/ pubmed/11014406
Chenoweth MJ, O’Loughlin J, Sylvestre MP, Tyndale RF. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenet Genomics 2013; 23(4): 232-5.https://www.ncbi.nlm.nih.gov/pubmed/23462429
Yang M, Kunugita N, Kitagawa K, et al. Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. Cancer Epidemiol Biomarkers Prev 2001; 10(6): 589-93.
Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006; 80(3): 282-97.https://www.ncbi.nlm.nih.gov/pubmed/16952495
Kim S. Overview of Cotinine Cutoff Values for Smoking Status Classification. Int J Environ Res Public Health 2016; 13(12): 1236.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201377/